SMOKING CESSATION COUNSELLING

Tobacco use is the leading preventable cause of premature morbidity and death in the world and it is responsible for approximately 15 years of healthy life lost. The world average smoking prevalence is 21% (35% for men and 6% for women), with the worst situation in low- and middle-income countries. In the Russian Federation, 31% of adults smoke (51% of men and 14% of women); meanwhile in the last decade the prevalence of smoking declines by about 1% per year. From a clinical standpoint, smoking is a behavioral disorder caused by psychophysical dependence from nicotine. Tobacco dependence is associated with the characteristic smoking habits and withdrawal symptoms that prevent successful cessation. The role of physician is to identify smokers on a regular basis, increase their readiness to quit, and support them during a quit attempt. Smoking status should be assessed in any patient who seeks medical care. All tobacco users should be encouraged to quit in a clear and personalized manner. The further content of medical care is determined by the patient’s willingness to make a quit attempt. For those who are not ready to discuss smoking cessation, physician should express readiness to help in a quit attempt at any time. For the patients who are not ready to quit at this time, physician should initiate brief motivational intervention and discuss possible benefits of smoking cessation and obstacles to successful quitting. For those who are ready to quit, physician provides behavioral counselling and prescribes medications (nicotine replacement therapy or nicotinic receptor partial agonists). At the follow-up visits in a week and a month after the quit date, physician should discuss treatment effectiveness and problems with smoking habits. For continued smokers physician should reassess their readiness to quit at the following visits and repeat motivational interviewing. Screening tests for smoking-related diseases should be recommended when necessary.

tobacco use disorder, smoking cessation, motivational interviewing, tobacco use cessation products

1. WHO report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: World Health Organization. 2017; 263 p.

2. Глобальный опрос взрослого населения о пот реблении табака: Российская Федерация. Краткий обзор, 2016 г. Копенгаген: Европейское региональное бюро ВОЗ. 2016; 9 с. Global Adult Tobac co Survey: Russian Federation. Executive summary 2016. Copenhagen: World Health Organization Regional Office for Europe. 2016; 9 p. [In Russian].

3. Centers for Disease Contro l and Prevention. Current Cigarette Smoking Among Adults—United States, 2016. Morbidity and Mortality Weekly Report. 2018; 67(2): 53-9 [accessed 2018 Feb 22].

4. Kim J., Fleming C.B., Catalano R.F. Individual and social influences on progression to daily smoking during adolescence. Pediatrics. 2009; 124(3): 895-902.

5. West R., Shiffman S. Fast Facts: Smoking Cessation. Second edition. Health Press Limited, Oxford, UK. 2007; 81 p.

6. Toolkit for delivering the 5A’s and 5R’s brief t obacco interventions in primary care. Geneva: World Health Organization. 2014.

7. Миллер У.Р., Роллник С. Мотивационное консультирование: как помочь людям изм ениться. М.: Эксмо. 2017; 544 с. Miller W.R., Rollnick S. Motivational Interviewing: Preparing People for Change. М.: Eksmo. 2017; 544 р

8. Cahill K., Stevens S., Perera R. et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013; 5:CD009329. doi: 10.1002/14651858. CD009329.pub2.

9. Leaviss J., Sullivan W., Ren S., et al. What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economi c evaluation. Health Technol Assess. 2014; 18(33): 1-120.

10. Anthenelli R.M., Benowitz N.L., West R., at al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and wit hout psychiatric disorders (EAGLES): a doubleblind, randomised, placebo-controlled clinical trial. Lancet. 2016; 387(10037): 2507-20.

11. Benowitz N.L., Pipe A., West R., at al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smok ers: A Randomized Clinical Trial. JAMA Intern Med. Published online April 09, 2018. doi:10.1001/jamainternmed.2018.0397.

12. The Guide to Clinical Preventive Services 2014: Recommendations of the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality ( US). 2014; 123 р.